Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 5/2022

19.07.2022 | Invited Review Article

Evolving Roles of Optimal Medical Therapy and PCI in Chronic Coronary Syndrome Patients with Stable Angina: Introduction

verfasst von: William E. Boden, Juan Carlos Kaski

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

This Introduction sets the stage for 5 subsequent papers that will follow, and which describe several key features of the ISCHEMIA Trial in depth, including clinical outcomes, beginning with a detailed discussion by Dr. David L. Brown from Washington University, St. Louis, MO on the “importance of OMT in the management of CCS patients” and how the results of ISCHEMIA reinforce the findings of earlier strategy trials in CCS patients. Drs. Rasha Al-Lamee and Darrel Francis from Royal College of London, UK, will discuss the important topic of “how to assess quality of life improvement with revascularization in CCS patients with chronic angina and lessons learned the ORBITA trial, including the importance of unblinded vs. blinded trials”. Drs. Kreton Mavromatis from Emory University, Atlanta, GA and Eric Bates from the University of Michigan, Ann Arbor, MI, will next discuss whether (and how) the “role of revascularization and, in particular, PCI in CCS patients has changed following the publication of the ISCHEMIA Trial”, followed by a paper highlighting the important role of assessing myocardial ischemia and no obstructive coronary arteries (INOCA) in patients with CCS and why this represents both an under-diagnosed and under-treated cause of chronic angina, especially in women with suspected CAD. Finally, the concluding paper by Drs. Boden, Kaski, and Bernard Gersh from the Mayo Clinic, Rochester, MN, will summarize “the future of managing chronic stable angina and how best to synthesize recent clinical trials evidence with evolving CCS management guidelines”.
Literatur
1.
Zurück zum Zitat Sackett D. How to read clinical journals: I. why to read them and how to start reading them critically. Can Med Assoc J. 1981;124(5):555–8. Sackett D. How to read clinical journals: I. why to read them and how to start reading them critically. Can Med Assoc J. 1981;124(5):555–8.
2.
Zurück zum Zitat Guyatt G. Evidence-based medicine. Ann Intern Med. 1991;14(2):A-16–23. Guyatt G. Evidence-based medicine. Ann Intern Med. 1991;14(2):A-16–23.
3.
Zurück zum Zitat Rosenberg W, Donald A. Evidence based medicine: an approach to clinical problem-solving. BMJ (Clin Res Ed). 1995;310:1122–6.CrossRef Rosenberg W, Donald A. Evidence based medicine: an approach to clinical problem-solving. BMJ (Clin Res Ed). 1995;310:1122–6.CrossRef
4.
Zurück zum Zitat Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. Ann Thorac Surg. 1968;5:334–9.CrossRef Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. Ann Thorac Surg. 1968;5:334–9.CrossRef
5.
Zurück zum Zitat Gruentzig AR. Percutaneous transluminal coronary angioplasty. Semin Roentgenol. 1981;16:152–3.CrossRef Gruentzig AR. Percutaneous transluminal coronary angioplasty. Semin Roentgenol. 1981;16:152–3.CrossRef
6.
Zurück zum Zitat Takaro T, Hultgren HN, Lipton MJ, Detre KM. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions. Circ. 1976;54:III107–17. Takaro T, Hultgren HN, Lipton MJ, Detre KM. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions. Circ. 1976;54:III107–17.
7.
Zurück zum Zitat Fisher L, CASS Principal Investigators and their Associates. Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery bypass surgery: survival data. Circ. 1983;68:939–50.CrossRef Fisher L, CASS Principal Investigators and their Associates. Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery bypass surgery: survival data. Circ. 1983;68:939–50.CrossRef
8.
Zurück zum Zitat Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized controlled trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators: Part 2 of 2. The Online Journal of Current Clinical Trials. Lancet. 1994;344:1446–58. Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized controlled trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators: Part 2 of 2. The Online Journal of Current Clinical Trials. Lancet. 1994;344:1446–58.
9.
Zurück zum Zitat Parisi AF, Folland ED, Hartigan P, et al. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med. 1992;326:10–6.CrossRef Parisi AF, Folland ED, Hartigan P, et al. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med. 1992;326:10–6.CrossRef
10.
Zurück zum Zitat RITA-2 Study Group. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997, 350:461–8. RITA-2 Study Group. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997, 350:461–8.
11.
Zurück zum Zitat Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.CrossRef Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.CrossRef
12.
Zurück zum Zitat The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.CrossRef The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.CrossRef
13.
Zurück zum Zitat De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve–guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001.CrossRef De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve–guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001.CrossRef
14.
Zurück zum Zitat De Bruyne B, Fearon WF, Pijls NHJ, et al. Fractional flow reserve–guided PCI for stable coronary artery disease. N Engl J Med. 2014;371:1208–17.CrossRef De Bruyne B, Fearon WF, Pijls NHJ, et al. Fractional flow reserve–guided PCI for stable coronary artery disease. N Engl J Med. 2014;371:1208–17.CrossRef
15.
Zurück zum Zitat Xaplanteris P, Fournier S, NHJ P, Fearon WF, Barbato E, PAL T, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018;379:250–9.CrossRef Xaplanteris P, Fournier S, NHJ P, Fearon WF, Barbato E, PAL T, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018;379:250–9.CrossRef
16.
Zurück zum Zitat Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395–407.CrossRef Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395–407.CrossRef
17.
Zurück zum Zitat Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med. 2020;382:1408–19.CrossRef Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med. 2020;382:1408–19.CrossRef
18.
Zurück zum Zitat Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677–87.CrossRef Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677–87.CrossRef
19.
Zurück zum Zitat Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LEJ, Friedman JD. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012–24.CrossRef Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LEJ, Friedman JD. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012–24.CrossRef
20.
Zurück zum Zitat Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circ. 2003;107:2900–7.CrossRef Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circ. 2003;107:2900–7.CrossRef
21.
Zurück zum Zitat Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232–40.CrossRef Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232–40.CrossRef
22.
Zurück zum Zitat Al-Lamee R, Thompson D, Dehbi H-M, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31–40.CrossRef Al-Lamee R, Thompson D, Dehbi H-M, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31–40.CrossRef
Metadaten
Titel
Evolving Roles of Optimal Medical Therapy and PCI in Chronic Coronary Syndrome Patients with Stable Angina: Introduction
verfasst von
William E. Boden
Juan Carlos Kaski
Publikationsdatum
19.07.2022
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5/2022
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07185-z

Weitere Artikel der Ausgabe 5/2022

Cardiovascular Drugs and Therapy 5/2022 Zur Ausgabe

So beeinflussen Herzinfarkte auf lange Sicht die Sterblichkeit

20.06.2024 ST-Hebungsinfarkt Nachrichten

Wie hoch ist bei Patienten, die nach einem ST-Hebungs-Myokardinfarkt die initiale Hochrisikophase überleben, auf lange Sicht das Sterberisiko? Eine Studie aus Dänemark liefert dazu nun aufschlussreiche Daten.

Protonenpumpenhemmer stoppt Arrhythmie

20.06.2024 Protonenpumpenhemmstoffe Nachrichten

Wenn Nervenfasern aus dem Magen und dem Herzen im Gehirn dicht beieinander liegen, kann auch mal etwas schiefgehen: So lässt sich erklären, weshalb Schmerzen durch einen Magentumor bei einem Mann eine ventrikuläre Extrasystolie auslösen – und PPI diese beenden.

Ob Apixaban nützt oder schadet, entscheidet der CHA2DS2-VASc-Score

20.06.2024 Therapie des Vorhofflimmerns Nachrichten

Patienten mit subklinischem Vorhofflimmern tragen ein erhöhtes Risiko für Schlaganfälle. Da stellt sich die Frage nach einer medikamentösen Antikoagulation. Offenbar hängt es aber vom CHA2DS2-VASc-Score ab, ob die Gabe von Apixaban von Vorteil ist.

Wie SGLT2-Hemmer es schaffen, die Mortalität zu reduzieren

20.06.2024 Kardiologische Therapie Nachrichten

SGLT2-Hemmer verhindern keine Herzinfarkte oder Schlaganfälle. Aber sie reduzieren die kardiovaskuläre Mortalität bei einem breiten Spektrum von Patienten. Wie sie das schaffen, verdeutlicht eine Metaanalyse von Daten aus elf randomisierten Studien.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.